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Research Article
Faecal haemoglobin concentration thresholds
for reassurance and urgent investigation for colorectal
cancer based on a faecal immunochemical test in
symptomatic patients in primary care
Craig Mowat1, Jayne Digby2 , Judith A Strachan3, Rebecca K McCann3,
Francis A Carey4, Callum G Fraser2 and Robert JC Steele2
Abstract
Background: Faecal haemoglobin concentration (f-Hb), estimated using a faecal immunochemical test, can be safely
implemented in primary care to assess risk of colorectal cancer (CRC). Clinical outcomes of patients presenting with
symptoms of lower gastrointestinal disease were examined using an extensive range of f-Hb thresholds to decide on
reassurance or referral for further investigation.
Methods: All patients who attended primary care and submitted a single faecal specimen faecal immunochemical test in
the first year of the routine service had f-Hb estimated using HM-JACKarc: f-Hb thresholds from <2 to5 400 mg Hb/g
faeces (mg/g) were examined.
Results: Low f-Hb thresholds of <2, <7, <10 and <20mg/g gave respective CRC risks of 0.1, 0.3, 0.3 and 0.4%,
numbers needed to scope for one CRC of 871, 335, 300 and 249, and ‘false negative’ rates of 2.9, 11.4, 13.3 and 17.1%.
With thresholds of <2, <7, <10 and <20mg/g, 48.6, 74.6, 78.1 and 83.2% respectively of symptomatic patients could be
managed without further investigation. With reassurance thresholds of <2 mg/g, <7 mg/g and <10 mg/g, the thresholds
for referral for urgent investigation would be >400 mg/g, 5200 mg/g and 5100 mg/g. However, patients with a f-Hb
concentration of <10 or <20 mg/g with iron deficiency anaemia, or with severe or persistent symptoms, should not be
denied further investigation.
Conclusions: In primary care, f-Hb, in conjunction with clinical assessment, can safely and objectively determine
individual risk of CRC and decide on simple reassurance or urgent, or routine referral.
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Lower gastrointestinal (GI) symptoms are poor predic-
tors of colorectal cancer (CRC), and other serious
bowel disease.1 When guidance on the ‘two week
wait’ for urgent referral for further investigation of
patients with symptoms suspicious of CRC was intro-
duced in England, this led to a large increase in refer-
rals, but no change in the stage of diagnosis of CRC.2
In addition, in a recent study, patients from primary
care practices with the highest urgent suspected cancer
referral rates did not have lower likelihood of late stage
diagnosis than those from practices with lower referral
rates.3
The problem with relying on symptoms alone is that
all potentially caused by CRC are often due to non-
significant or functional disorders.1 This is com-
pounded by the fact that current guidance, both from
Scottish Government4 and the National Institute for
Health and Care Excellence (NICE) in England,5,6
has serious limitations, since it is mainly based on the
presenting symptoms and, in the latter, very dependent
on age. In addition, NICE are currently engaged in
considering development of guidance on quantitative
faecal immunochemical tests (FIT) to guide CRC refer-
ral for patients presenting in primary care with a
change in bowel habit or abdominal pain.7
The available current guidance in the UK is complex
and open to wide interpretation by general practi-
tioners (GP). However, there is burgeoning evidence
that using faecal haemoglobin concentration (f-Hb),
as estimated by quantitative FIT, allows a rational,
universal approach to identifying those symptomatic
patients who would benefit most from further investi-
gation8 and those who can be safely managed with
what we think is appropriately termed a ‘reassurance’
strategy. This strategy involves giving advice to
patients that their symptoms are unlikely to be due to
significant GI disease, but they should seek advice
should their symptoms return, continue, or worsen.
Further, it is now clear that FIT can be employed in
this context for all symptomatic patients, not only low-
risk9,10 as recommended in NICE NG126 and DG30,7
but also those who report high-risk symptoms,11–15
particularly rectal bleeding.16
However, uncertainty remains around a numerical f-
Hb threshold to discriminate between those who are
and are not likely to benefit from investigation. There
is even less consensus on the f-Hb threshold that should
trigger urgent investigation. For example, in response
to the severe constraints on colonoscopy delivery
imposed by the current COVID-19 pandemic,
National Health Service (NHS) England has recom-
mended a threshold of 100 mg/g for urgent investiga-
tion17 whereas similar guidance from NHS Scotland
recommends 400 mg/g.18 In an ideal world, there
would be no need to distinguish between urgent and
routine referrals but this is currently unrealistic in the
United Kingdom (UK) and probably in many other
countries. The need for a rational approach to deter-
mining which patients with symptoms should be fur-
ther investigated urgently will continue for the
foreseeable future.19
Therefore, when using f-Hb as an aid to categorizing
patients with lower GI symptoms, it is crucial to be
able to decide on thresholds for reassurance and
urgent referral based on robust data that encompass
the complete range of possible f-Hb thresholds. In
addition, for FIT to have maximum benefit in terms
of efficient utilization of services and reassurance of
patients, it is essential, in our view, that it is employed
in primary care and is requested, with few exceptions,
on every patient who presents with lower GI
symptoms.20,21
For these reasons, the CRC diagnostic outcomes
across a comprehensive range of f-Hb thresholds in a
wide spectrum of patients who presented with lower GI
symptoms and had FIT in primary care were studied.
These data were collected over a one-year period in a
region in which GPs have been encouraged since 2015
to use FIT in such patients regardless of the specific
symptoms, and to use f-Hb <10 mg/g as an indication
for reassurance without referral for further investiga-
tion.20 The introduction of this service and the perfor-
mance of a 10 mg/g f-Hb threshold has been described
previously.14
Methods
In the NHS Tayside Board, FIT kits (Hitachi Chemical
Diagnostics Systems Co., Ltd, Tokyo, Japan, supplied
by Alpha Labs Ltd, Eastleigh, Hants, UK) were made
available to GP practices beginning in December 2015.
GPs were recommended to request f-Hb to guide refer-
ral of patients with any lower GI symptoms, along with
a full blood count. Patients were requested to return
the completed FIT specimen collection device immedi-
ately to the GP facility and, from there, the devices
were delivered to Blood Sciences, Ninewells Hospital
and Medical School, Dundee, at ambient temperature,
by the routine sample collection service and, if
required, stored at 4 C prior to analysis. Analyses
were carried out from Monday through Friday; most
samples were analysed on the day of receipt and results
reported electronically to the requesting GP after f-Hb
measurement using one HM-JACKarc (Hitachi
Chemical Diagnostics Systems) FIT system which has
a limit of detection (LoD) of 2 lg/g, a limit of quanti-
tation (LoQ) of 7 lg/g and an upper measurement limit
of 400 mg/g.22 Samples with results above the upper
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measurement limit were therefore reported as >400 lg/
g. In our routine practice, using a single threshold, as
previously described in detail,14 patients with f-
Hb5 10 mg/g were defined as worthy of further inves-
tigation as recommended in NICE DG30.6 The reports
also sign-posted GPs to web-based advice that f-Hb
<10 mg/g, in the absence of iron deficiency anaemia
(IDA), severe persistent symptoms, or a rectal or
abdominal mass, suggests that CRC is extremely
unlikely.
Numerical FIT results generated from 7 December
2015 to 7 December 2016 were retrieved from the lab-
oratory database and linked, using the Community
Health Index (CHI) number, with the electronic patient
record to access all correspondence, laboratory results,
referrals to secondary care, colonoscopy findings, hos-
pital admissions and attendances at the primary care
out-of-hours service. In addition, in December 2018,
the Health Informatics Centre, University of Dundee,
used the CHI number of all patients who had submit-
ted a FIT to the laboratory to perform a post-hoc ano-
nymized record linkage with the Scottish Cancer
Registry (SCR). This was carried out in order to iden-
tify any cases of CRC that had been overlooked
(International Classification of Diseases [ICD] codes
C18, C19 and C20). All cases of CRC were confirmed
histologically. MedCalc statistical software (MedCalc
Software, Mariakerke, Belgium) was employed for
calculations.
Results
The data presented here include all patients in the study
period who presented to their GP and had a f-Hb
result, irrespective of whether they had been referred
or investigated further. The results are given in Tables 1
to 4.
Table 1 shows the performance of FIT in patients
with symptoms at a range of f-Hb thresholds that could
be used to define a f-Hb that made a diagnosis of CRC
very unlikely (i.e., the f-Hb that the GP could use to
provide reassurance to the patient that significant GI
disease was absent): note that the sixth column gives
the number of CRC that were not initially referred in
response to the f-Hb.
Table 2 shows the performance at a range of f-Hb
thresholds that could be used to define a result that
could make the diagnosis of CRC more likely (i.e.,
the results that the GP could use to justify referral
for further investigation).
Table 3 shows the risk of CRC associated with four
f-Hb values that might be used to direct patients into
the reassurance category (<2, <7, <10 and <20 mg/g)
and the full range of f-Hb thresholds up to 5400 mg/g
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along with the proportion of all patients represented.
The lower f-Hb values were chosen because 2mg/g is
the LoD, 7 mg/g is the LoQ, <10 mg/g was used as the
value that was communicated to the GP as a robust
indication that, with the exceptions noted earlier, fur-
ther investigation was not generally required, as per
NICE DG306 and <20 mg/g has been recommended
as the most appropriate f-Hb value for the rather dif-
ferent clinical setting of asymptomatic population
screening for CRC23 and has been used in assessment
of symptomatic patients in at least one other study.24
Table 4 shows the characteristics of all the patients
with a f-Hb <20 mg/g who were diagnosed with CRC,
either as a result of their initial referral immediately
after the f-Hb result, or subsequently identified
by interrogating the available databases or linkage
to the SCR.
Discussion
In a previous publication,14 we described in consider-
able detail the implementation of a routine FIT service
in primary care as an adjunct to diagnostic decision-
making, using a threshold of <10 mg/g that would indi-
cate that it was sufficiently unlikely to have CRC to
warrant the approach we term ‘reassurance’. The use of
FIT was not mandated, but the number of requests
increased steadily, and, overall, 70.5% of referrals for
investigation were accompanied by a request for FIT.
Of the f-Hb recorded that were not associated with an
immediate referral (n¼ 2521), 95.3% were <10 mg/g.
However, the f-Hb was not used as a rigid criterion
to exclude patients from investigation and, of those
patients who were referred (n¼ 2848), 63.0% had a f-
Hb <10 mg/g. The introduction of this service led to an
overall reduction in referrals to secondary care of
15.1% in the first year, and of those not immediately
referred, only six (0.2%) were subsequently diagnosed
with CRC, with no evidence of adverse outcome from
diagnostic delay.
The diagnostic outcomes associated with a wide
range of f-Hb thresholds have been documented here
to assist in making a rational decision as to which
thresholds to use for advocating reassurance and for
indicating the need for urgent or other further
investigation.
A threshold of <10 mg/g is now widely used in
assessment of patients with symptoms. The evidence
supporting this is largely based on the first studies on
FIT in the symptomatic done in Scotland which docu-
mented receiver operating characteristic analyses that
gave the optimum balance between sensitivity and spe-
cificity for CRC detection as 10 mg/g,25,26 supported by
a larger similar study from Spain.27 Others have used
different thresholds.21 However, because some CRC do
have f-Hb below the NICE DG30 recommended
threshold,6 interest focused (before the COVID-19 pan-
demic) on use of lower f-Hb thresholds, approaching
the LoD and LoQ of the FIT system used.22 These
include undetectable,20 2,11 4,12,28 and 7mg/g.29,30
CRC detection did improve at lower f-Hb thresholds
with higher clinical sensitivity, but at the expense of
higher positivity and colonoscopy demand, and lower
positive predictive value (PPV).
Table 2. Test performance of FIT above different faecal haemoglobin concentration (f-Hb) thresholds (mg Hb/g faeces for colorectal
cancer (CRC) in all patients with f-Hb.
f-Hb threshold




















52 2767 51.4% 2665 102 97.1% (91.9–99.4) 96.3% (95.5–97.0) 3.7% (3.5–3.8) 27
57 1365 25.4% 1272 93 88.6% (80.9–94.0) 93.2% (91.7–94.4) 6.8% (6.3–7.4) 15
510 1177 21.9% 1086 91 86.7% (78.6–92.5) 92.3% (90.6–93.7) 7.7% (7.1–8.4) 13
520 904 16.8% 817 87 82.9% (74.3–89.5) 90.4% (88.2–92.2) 9.6% (8.7–10.6) 10
550 648 12.0% 570 78 74.3% (64.8–82.3) 88.0% (85.1–90.3) 12.0% (10.7–13.6) 8
5100 503 9.3% 430 73 69.5% (59.8–78.1) 85.5% (82.0–88.4) 14.5% (12.7–16.6) 7
5150 419 7.8% 352 67 63.8% (53.9–73.0) 84.0% (80.1–87.3) 16.0% (13.8–18.5) 6
5200 378 7.0% 313 65 61.9% (51.9–71.2) 82.8% (78.5–86.4) 17.2% (14.7–20.0) 6
5250 348 6.5% 286 62 59.0% (49.0–68.6) 82.2% (77.7–86.0) 17.8% (15.1–20.9) 6
5300 320 5.9% 261 59 56.2% (46.2–65.9) 81.6% (76.8–85.6) 18.4% (15.5–21.7) 5
5350 304 5.6% 247 57 54.3% (44.3–64.0) 81.3% (76.3–85.4) 18.8% (15.7–22.2) 5
5400 292 5.4% 236 56 53.3% (43.3–63.1) 80.8% (75.7–85.1) 19.2% (16.0–22.8) 5
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In contrast, few have studied higher f-Hb thresholds
but, because of the imperative to prioritize patients for
further investigation in the current COVID-19 pan-
demic, a f-Hb threshold of 100 mg/g has been suggested
for England despite the clinical characteristics being
unknown at present.17 Others have proposed 150 mg/g
for use as a threshold in assessment of patients with
symptoms,31,32 the rationale being that this threshold
gives positivity approximating to that found in the past
in the NHS Bowel Cancer Screening Programme with
guaiac faecal occult blood tests.33
However, the dataset provided here can be used to
guide a rational choice of numerical f-Hb thresholds
for use in primary care to guide the investigation of
symptomatic patients. Table 1 shows that reassurance
f-Hb thresholds of 2, 7, 10 and 20 mg/g give respective
CRC risks of 0.1, 0.3, 0.3 and 0.4%, numbers needed to
scope for one CRC of 871, 335, 300 and 249, and ‘false
negative’ rates of 2.9, 11.4, 13.3 and 17.1%. When colo-
noscopy is employed as a first-line asymptomatic pop-
ulation screening test, it has been reported that
investigation of 111 asymptomatic individuals between
the ages of 50 and 66 years is needed to detect one
CRC34; thus, the use of FIT in symptomatic patients
is extremely effective at identifying those at lower risk
than the asymptomatic population at large. In addi-
tion, since colonoscopy in England is associated with
a 7.4% ‘false negative rate’ as assessed by the three-
year post-colonoscopy CRC rate,35 a f-Hb threshold of
2 mg/g could be said to perform better than colonosco-
py for reassurance that significant disease is absent.
It is important to stress, however, that, unlike colo-
noscopy, FIT is not a diagnostic test, but rather an aid
to diagnosis and, in our initial experience, a f-Hb of
<10 mg/g did not deter GPs from referring patients
when a rational clinical indication existed. However,
as GPs gain further confidence in FIT, it is likely that
referral of patients with low f-Hb will become less
common. The reassurance threshold chosen will have
a direct effect on colonoscopy demand, and using
thresholds of 2, 7, 10, or 20 mg/g would mean that
48.6, 74.6, 78.1 and 83.2% respectively of the symp-
tomatic population could be managed without further
investigation.
However, no matter what f-Hb reassurance thresh-
old is used, some CRC will be missed, and it pays
Table 4. Characteristics of all the patients with faecal haemoglobin concentration (f-Hb) <20mg Hb/g faeces who were diagnosed
with CRC, either as a result of their initial referral immediately after the result or subsequently identified by interrogating the available










Size (mm) Tumour Site
Dukes’
Stage
0 65 M Pelvic pain, weight loss No 126a ? Rectum ?
1 78 M Change of bowel habit No 120a 26 Ascending Colon A
1 83 F Weight loss, change
of bowel habit,
rectal bleeding
103a ? Caecum D
2 61 F Alternating diarrhoea/
constipation
No 139 ? Transverse D
2.5 89 M Diarrhoea Yes 71a 17 Transverse A
3 74 F Diarrhoea Yes 102a 60 Caecum ?
3 87 F Fatigue Yes 108a 28 Caecum A
3 67 M Change of bowel habit,
weight loss
No 162 32 Transverse Colon D
5 84 F Weight loss No 98a ? Caecum D
5 70 M Abdo Pain No 151 53 Splenic Flexure C
6 76 M Change of bowel habit Yes 138 ? Caecum ?
7 54 F Diarrhoea Yes 150 30 Rectum A
7 58 M Rectal bleeding Yes 134 ? ? ?
10 66 M Change of bowel habit Yes 94a 57 Transverse Colon B
10 50 F Change of bowel habit Yes 154 67 Caecum B
11 77 F Diarrhoea Yes 150 15 Rectum A
12 80 M Rectal Bleeding Yes 123a 32 Sigmoid Colon C
18 82 F Fatigue Yes 103a 40 Caecum B
aAnaemia.
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dividends to look at the characteristics of the patients
found to have CRC, but with f-Hb <20 mg/g. This
allows a logical approach to safety-netting for those
patients with low f-Hb, and Table 4 shows that 9 of
the 18 patients (50.0%) with f-Hb concentrations of
<20 mg/g who were found to have CRC had anaemia
(with an iron deficiency pattern). Therefore, a patient
with a f-Hb concentration of <10 or <20 mg Hb/g
faeces with iron deficiency anaemia (IDA), or with
severe and persistent symptoms, should undergo fur-
ther investigation. It is also important to recognize
the clinical experience and expertise of GPs in assessing
the nature and severity of symptoms: ‘gut feelings for
cancer’ can be conceptualized as a rapid summing up of
multiple verbal and non-verbal patient cues.36 Thus, f-
Hb should not be used by secondary care to refuse
requests from GPs to have a patient investigated, but
rather it should be used by the GPs themselves to assist
in reaching an objective decision as to whether or not
to refer for further investigation.
Unsurprisingly, the focus of research into FIT for
symptomatic patients has been on the ‘reassurance’ f-
Hb threshold as this affects demand for bowel investi-
gation. It would be ideal to be able to offer prompt
investigation to everyone with f-Hb higher than the
reassurance threshold but, with current constraints,
determining thresholds to distinguish between patients
requiring no, routine or urgent, investigation is neces-
sary for efficient and effective patient care. Germane to
deciding an appropriate threshold in this context is the
decision taken by the NICE Guideline Development
Group responsible for the generation of NG125; it
was agreed to use a 3% PPV threshold value to under-
pin the recommendations for urgent investigation for
suspected cancer. If the data presented here are treated
as dichotomous, then all symptomatic patients with a f-
Hb <400 mg/g had a PPV for CRC of under 3%
(Table 1) but if a subset of patients with a low f-Hb
(<2, <7, <10 or <20 mg/g) are to be reassured and not
investigated, this markedly changes the significance of
higher thresholds (Table 2).
As shown in Table 3, the risk of CRC when the f-Hb
is in the intermediate range between the reassurance
and urgent investigation thresholds varies owing to
changes in the numbers of patients embraced within
the intermediate range. Thus, with a reassurance f-Hb
threshold of <2 mg/g, the risk does not approach 3% in
any of the intermediate ranges, so that a f-Hb threshold
of 5400 mg/g would seem appropriate for urgent inves-
tigation. However, with a reassurance threshold of
<7 mg/g, a CRC risk of 3% is reached at the 7–
249 mg/g f-Hb range, so that a threshold for urgent
referral of 5200 mg/g could be employed, and, using
the same logic, with a reassurance threshold of
<10 mg/g, the threshold for urgent referral would be
5100 mg/g. Were a reassurance threshold of <20 mg/g
to be employed, no intermediate range PPV falls below
3%, so that every patient with a f-Hb 520 mg/g would
be classified as requiring urgent investigation, but this
group would only make up 16.8% of patients present-
ing with symptoms.
Interestingly, an economic evaluation carried out for
the UK National Screening Committee estimated that
the most cost-effective approach to CRC screening is
biennial FIT at a threshold of 20 mg/g in the 50–74 age
range,23 which would give a positivity rate of around
8% in participants.33 Thus, if a reassurance threshold
of <20 mg/g was adopted for symptomatic patients,
which would give a positivity rate of 16.8%, the same
threshold could be adopted for participants in screen-
ing and for symptomatic patients. This would have the
virtue of simplicity and, if the reassurance threshold
was adhered to for patients with symptoms, with the
proviso of adequate safety-netting, the reduction in
demand for symptomatic bowel investigation could
be sufficient to accommodate much lower screening f-
Hb thresholds than those currently used in the UK.
The main strength of this study, setting it apart from
most literature on this topic, is that the data were
derived from a real-life situation where GP have been
employing routine FIT as an adjunct to diagnosis in all
patients presenting with lower GI symptoms, including
rectal bleeding. In addition, linkage to the SCR pro-
vides assurance that a subsequent diagnosis of CRC in
a patient with f-Hb <20 mg/g but not initially referred
was extremely rare.
The main weakness is that only CRC was considered
and data on other important conditions, especially
higher risk adenomas and inflammatory bowel disease,
are not presented. This is because colonoscopy data
would have been necessary for these data to have
been accurately assessed, and only 53.1% of patients
with a f-Hb result were referred for investigation. In
addition, the focus of waiting time targets for symp-
tomatic patients is focused on CRC detection.
Moreover, since different FIT systems do not give the
same numerical estimates of f-Hb,37 the numerical data
here may not be transferrable across systems.
Conclusions
Current evidence clearly points to moving away from
the assessment of specific presenting symptoms to
determine a patient’s CRC risk towards a FIT-based
algorithm with symptoms as the entry point. The work
presented here, building on a recent study done in three
NHS Boards in Scotland38 and performed according to
the STARD (Standards For Reporting Diagnostic
Accuracy Studies) guidelines on assessing diagnostic
accuracy,39 and in our previous publication,14 provides
Mowat et al. 7
compelling evidence that FIT can be employed safely in
primary care. In addition, the detailed presentation of
the effect of a range of f-Hb thresholds provides a guide
as to how FIT can best be used, and sets out the impli-
cations of varying the f-Hb threshold used to determine
the need to refer a patient for investigation of lower GI
symptoms.
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